FLAURA
Osimertinib in Untreated EGFR-Mutated Advanced NSCLC
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 556 patients with untreated EGFR-mutated advanced NSCLC, osimertinib improved progression-free and overall survival compared with first-generation EGFR-TKI (gefitinib or erlotinib).
N
556
Design
Double-blind RCT
Endpunkt
Progression-free survival
Relevanz
2
ErgebnisPFS 18.9 vs 10.2 months (HR 0.46). OS 38.6 vs 31.8 months (HR 0.80).
Soria JC, et al. N Engl J Med. 2018;378(2):113-125; Ramalingam SS, et al. N Engl J Med. 2020;382(1):41-50. 10.1056/NEJMoa1713137
Diskussion & Kritik
Established osimertinib as first-line standard in EGFR-mutated NSCLC; superseded by FLAURA2 (osimertinib + chemo) in fit patients with high-risk features.